HCV Treatment
EASL 2016: ABT-493 + ABT-530 Works Well for Patients Who Did Not Respond to Prior DAAs
- Details
- Category: Experimental HCV Drugs
- Published on Tuesday, 03 May 2016 00:00
- Written by Michael Carter
An experimental combination of direct acting antivirals (DAAs) from AbbVie is effective and safe in patients with hepatitis C virus (HCV) genotype 1 who did not respond to previous DAA therapy, according to research presented at the European Association for the Study of the Liver's International Liver Congress (EASL 2016) last month in Barcelona. Between 86% and 100% of patients achieved sustained virological response and the combination worked well in the context of pre-existing resistance mutations.
EASL 2016: Portugal's Roll-Out of Hepatitis C DAA Therapy Achieves Impressive Outcomes
- Details
- Category: HCV Treatment
- Published on Wednesday, 27 April 2016 00:00
- Written by Michael Carter
Roll-out of hepatitis C therapy using direct-acting antivirals (DAAs) has achieved excellent outcomes in Portugal, data presented to the International Liver Congress in Barcelona shows. Overall, 96% of treated patients had a sustained virological response (SVR) to therapy, with a 100% response rate seen in some sub-groups. Treatment also worked well for people with liver cirrhosis and treatment response was unaffected by HIV coinfection, previous hepatitis C therapy, or older age.
EASL 2016: DAAs for Hepatitis C Achieve Excellent Outcomes in Real-World Settings
- Details
- Category: Approved HCV Drugs
- Published on Friday, 22 April 2016 00:00
- Written by Michael Carter
Hepatitis C therapy with direct acting antivirals (DAAs) is as effective in real-world settings as it was in clinical trials, according to U.S. research presented at the International Liver Congress in Barcelona last week. Investigators from the Department of Veteran Affairs (VA) analyzed outcomes in over 9000 patients treated with DAA combinations. Outcomes were excellent, with 2 combinations achieving cure rates of 93%, similar to those seen in randomized studies with strict eligibility criteria and close follow-up.
EASL 2016: AbbVie Pangenotypic Combination Achieves High Cure Rate for Genotype 3 Hepatitis C
- Details
- Category: Experimental HCV Drugs
- Published on Friday, 22 April 2016 00:00
- Written by Keith Alcorn
A new combination of direct-acting antivirals developed by AbbVie -- ABT493 and ABT-530 -- is highly effective in curing people with genotype 3 hepatitis C virus (HCV) infection and liver cirrhosis, according to results from a pair of Phase 2 studies presented at last week’s EASL International Liver Congress (EASL 2016) in Barcelona.
EASL 2016: Vaccines for HIV and Hepatitis C Could Potentially Be Administered Together
- Details
- Category: Experimental HCV Drugs
- Published on Friday, 22 April 2016 00:00
- Written by EASL
Immunization against HIV and hepatitis C virus (HCV) could potentially be combined without compromising immune response to either, though effective vaccines for both diseases are still elusive, according to research presented at the European Association for the Study of the Liver's International Liver Congress (EASL 2016) last week in Barcelona.
More Articles...
- EASL 2016: Adolescents with Hepatitis C Achieve High Cure Rates with Sofosbuvir/Ledipasvir
- Coverage of the 2016 EASL International Liver Congress
- EASL 2016: Novel Therapy RG-101 Plus Antivirals Could Cure Hepatitis C in 4 Weeks
- EASL 2016: Shifting Hepatitis C Treatment to Primary Care Providers Could Expand Availability
Web Design and Development by